BHLH72 Antibody

Shipped with Ice Packs
In Stock

Product Specs

Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Lead Time
Made-to-order (14-16 weeks)
Synonyms
BHLH72 antibody; EN109 antibody; PIF7 antibody; At5g61270 antibody; MFB13.4 antibody; Transcription factor PIF7 antibody; Basic helix-loop-helix protein 72 antibody; AtbHLH72 antibody; bHLH 72 antibody; Phytochrome-interacting factor 7 antibody; Transcription factor EN 109 antibody; bHLH transcription factor bHLH072 antibody
Target Names
BHLH72
Uniprot No.

Target Background

Function
BHLH72 is a transcription factor that negatively regulates the phytochrome B signaling pathway under prolonged red light exposure. It plays a role in controlling PHYB abundance at the post-transcriptional level, potentially through the ubiquitin-proteasome pathway. BHLH72 may also regulate the expression of specific genes by binding to the G-box motif.
Gene References Into Functions
  1. BHLH72 regulates the expression of genes responsive to shade conditions. It recruits MRG1 and MRG2, which bind to H3K4me3/H3K36me3 and attract histone-acetylases to induce histone acetylation, promoting the expression of shade-responsive genes. PMID: 29187567
  2. Newly synthesized auxin, generated through a BHLH72-regulated pathway, is essential for shade-induced growth, directly connecting the perception of light quality signals to a rapid growth response. PMID: 22508725
  3. Research indicates that BHLH72 functions in the phyB signaling pathway under prolonged red light by maintaining low phyB protein levels, potentially in an additive or synergistic manner. PMID: 18252845
Database Links

KEGG: ath:AT5G61270

STRING: 3702.AT5G61270.1

UniGene: At.29114

Subcellular Location
Nucleus. Note=Migrates rapidly to speckles upon light exposure.
Tissue Specificity
Expressed in flowers.

Q&A

The BHLH72 antibody represents an emerging tool in antibody engineering, with applications in both basic research and therapeutic development. Below are structured FAQs addressing key scientific considerations, derived from current methodologies in antibody discovery and specificity engineering.

Advanced Research Questions

How can computational models resolve contradictions in BHLH72’s apparent cross-reactivity?

Discrepancies arise when ligands share overlapping epitopes. Solutions include:

  • Biophysics-informed energy modeling to disentangle binding modes for chemically similar ligands .

  • Network integration of transcriptomic data to identify pathways influencing off-target interactions (e.g., BCR signaling) .

Example Workflow

StepMethodPurpose
1Phage display selectionEnrich BHLH72 variants against target ligand
2High-throughput sequencingIdentify dominant clonotypes
3Energy function optimizationDesign variants with minimized off-target binding

What strategies optimize BHLH72’s affinity without compromising specificity?

  • Directed evolution: Iterative rounds of error-prone PCR coupled with yeast display screening .

  • Paratope engineering: Computational redesign of CDR loops using RosettaAntibody .

  • In vivo maturation: Transgenic mouse models expressing human Ig loci to refine affinity .

Methodological Challenges

How to address low-titer BHLH72 production in recombinant systems?

  • Codon optimization: Adjust coding sequences for improved expression in mammalian (e.g., HEK293) or microbial systems.

  • Chaperone co-expression: Co-express folding chaperones like Bip to reduce misfolding .

What controls are essential when interpreting BHLH72’s binding in immunohistochemistry?

  • Isotype-matched controls to rule out Fc-mediated binding.

  • Blocking peptides to confirm signal specificity .

  • Cell-line panels expressing varying levels of the target antigen .

Data Interpretation

How to distinguish genuine binding signals from assay artifacts in BHLH72 studies?

  • Dual-labeling experiments: Combine BHLH72 with a second antibody targeting a non-overlapping epitope.

  • Kinetic analysis: Surface plasmon resonance (SPR) to quantify on/off rates and identify non-specific avidity effects .

Key Validation Criteria

ParameterAcceptable Range
KD (SPR)≤10 nM
Cross-reactivity (ELISA)≤5% vs. homologs
Intra-assay CV<15%

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.